Zora Biosciences

Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test

Wed, Mar 17, 2021 08:05 CET

SECAUCUS, N.J. and HELSINKI, March 17, 2021 - Zora Biosciences Oy, a clinical diagnostics company whose mission is to identify robust markers of disease and develop them into high-throughput, health-economic value-added clinical methods, today announced it has signed a non-exclusive license agreement with Quest Diagnostics (NYSE: DGX), the world leader in diagnostic information services, for Zora's patented ceramide-analysis technology. Quest plans to develop a test service based on Zora's ceramide technology as an aid in identifying patients at risk for cardiovascular-related disease

LDL-Cholesterol Does Not Predict Heart Risk Among Heart Patients

Mon, Jun 24, 2019 09:05 CET

New Diagnostic Test, CERT, Improves Risk Prediction Over Standard Laboratory TestsEspoo, Finland, June 24, 2019 - New international study shows that LDL-cholesterol is unable to predict future cardiovascular events and fails to identify those coronary heart disease patients who are at the highest risk and who would benefit most from additional attention and preventive action. Cardiovascular diseases are the leading cause of death worldwide. In 2015, coronary heart disease affected 110 million people and resulted in 8.9 million deaths. Common belief is that coronary heart disease (CHD)

Share

Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test

LDL-Cholesterol Does Not Predict Heart Risk Among Heart Patients

Media